Back to results
US 11,596,688 B2Granted
Predicting outcome of treatment with an anti-α4β7 integrin antibody
AssigneeTakeda Pharmaceutical Company Limited
InventorsMaria Rosario, Timothy L. Wyant, Brihad Abhyankar
Life of this patent
Estimating the term…
Abstract
The invention provides methods for treating patients with anti-α4β7 antibody comprising predicting outcome of the antibody therapy. The invention relates to the identification of patients who can respond to therapy comprising an anti-α4β7 antibody.
Claims8
A method of treating a patient suffering from Inflammatory Bowel Disease (IBD), the method comprising
- a) measuring the serum concentration of vedolizumab in a patient, wherein the patient was administered an induction phase dosing regimen of vedolizumab at least two weeks prior,
- b) measuring the concentration of serum albumin in the patient,
- c) measuring the body weight of the patient;
- d) selecting a patient whose measurement of vedolizumab in step a) indicates low clearance, whose measurement of serum albumin in step b) is 3.8 to 5.0 g/dL, and whose body weight is <80 kg;
- and
- e) administering vedolizumab to the selected patient, thereby treating IBD.
3 more elements
A method of treating a patient having Crohn's disease, the method comprising
- a) measuring the serum concentration of vedolizumab in a patient having Crohn's disease, measuring the concentration of serum albumin in the patient, measuring the body weight of the patient, and measuring either SES-CD or MaRIA, wherein the patient was administered an induction phase dosing regimen of vedolizumab at least two weeks prior to the measurements,
- b) selecting a patient whose measurement of vedolizumab in step a) indicates low clearance, whose measurement of serum albumin in step a) is 3.5 to 5.0 g/dL, whose body weight is <80 kg;
- and whose SES-CD score <6 or MaRIA score <12, and
- c) administering vedolizumab to the selected patient, thereby treating Crohn's disease.
1 more element
Dependencies are inferred from the claim text.